Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Raytheon Technologies Corp (RTX) vs Tempus AI (TEM) Price & Performance

Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Raytheon Technologies Corp vs Tempus AI — how do they compare? Raytheon Technologies Corp trades at $223.97 (market cap $302.06B), while Tempus AI trades at $54.99 (market cap $9.93B). The key difference: Raytheon Technologies Corp is far larger — about 30.4× Tempus AI's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Tempus AI pays none. Which is the better fit depends on your goals.

RTXTEM
Market Cap
$302.06B$9.93B
Sector
IndustrialsBroad Market / Factor
52-Week High
$224.12$103.25
52-Week Low
$151.75$41.55
Enterprise Value
$332.61B$10.56B
Dividend Yield
1.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Raytheon Technologies Corp

RTX trades at $223.03, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a recent $515 million Navy radar contract. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $88.6 billion in 2025, and net income margin improved to 8.28%. The stock is near its consensus price target of $233.14, with no analyst sell ratings.

The outlook for RTX is positive, driven by defense contract wins and expanding profit margins, but risks include high valuation multiples and geopolitical uncertainties. Earnings growth and execution on backlog are key catalysts for further upside, though the stock's elevated P/E ratio of 39.27 warrants caution amid potential market volatility.

Tempus AI

Tempus AI (TEM) trades at $52.05, up 12.86% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat revenue estimates and raised 2026 sales guidance. The stock is technically bullish with moving averages supporting upside, while fundamentals show revenue growth to $1.4 billion in 2026 but persistent net losses. Recent news highlights expansion through the Personalis acquisition and AI-driven precision medicine advancements.

Outlook: Growth prospects are robust with AI adoption in healthcare and strategic deals, but high valuation ratios and negative profitability pose risks. Analysts are bullish with a $61.57 consensus target, though cash burn and competitive pressures require monitoring for sustained investor confidence.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.

Read more on RTX

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Read more on TEM